Intrathecal Cell Administration Rate Control for Neurological Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current intrathecal administration methods for therapeutic cells to treat neurodegenerative diseases are associated with adverse events such as back pain, lower limb pain, and cell clumping near the injection site, limiting the therapeutic dose and efficacy.
Innovation Solution
A method involving the intrathecal administration of a therapeutic cell suspension at a controlled rate of 0.1 to 2 ml/min, with a volume of 5 to 40 ml, and a cell concentration of 1×10^6 to 1×10^9 cells, while performing a lumbar puncture and optionally drawing cerebrospinal fluid to facilitate even distribution and minimize side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If intrathecal administration of therapeutic cells is performed at high dosage, then therapeutic efficacy is improved, but adverse events such as back pain, lower limb pain, and cell clumping increase
Solution Approach 1:
The patent performs a lumbar puncture before cell administration to create a controlled access pathway. This preliminary action allows for precise control of the administration process, enabling high cell dosages to be delivered while minimizing uncontrolled cell distribution and clumping that causes adverse events
Solution Approach 2:
The patent optimizes multiple parameters including administration rate (0.1-2 ml/min), cell concentration (1×10^6 to 1×10^9 cells), and suspension volume (5-40 ml). By carefully adjusting these parameters, the method achieves high therapeutic dosages while preventing cell clumping and reducing adverse events through controlled delivery conditions
2Productivity
If intrathecal administration rate is increased to deliver cells faster, then treatment time is reduced, but cell clumping near injection site increases
Solution Approach 1:
The patent employs a dynamic administration rate of 0.1-2 ml/min rather than a fixed rate. This allows the clinician to adjust the flow rate in real-time based on patient response and cell distribution patterns, maintaining productivity while preventing clumping by slowing down when cells begin to aggregate near the injection site
Solution Approach 2:
The method incorporates monitoring of cell distribution via MRI to provide feedback on administration effectiveness. This feedback loop allows adjustment of administration parameters to optimize cell distribution throughout the CNS while preventing localized clumping that would occur with excessively fast rates
Data Source
AI summary
The present invention provides methods of treating neurological diseases and disorders by intrathecal administration of cells, such as human stem cells, while the method provides a reduced rate of side effects associated with intrathecal administration.